In addition, numerous studies have suggested that vitiligo, while relatively uncommon with anti-PD-1 therapy (although up to 10% in melanoma patients), is associated with extremely high response rates (70–80%) across immunotherapies. The gene discussed is PDCD1; the disease is melanoma.